AMGN : Analysis & Opinions

  1. What Is Amgen’s New Target?

    March 2, 2015
    Amgen's investors are focusing a lot on its cholesterol-busting drug evolocumab; however, their research into biosimilars ...
  2. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  3. How Amgen Makes Billions On Just A Few Drugs

    November 5, 2014
    Amgen produces relatively few drugs, but that's doesn't mean it's any less essential or profitable. Here's a look at the ...
  4. Who are Amgen Inc.'s (AMGN) main competitors?

    August 27, 2014
    Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.
  5. 4 Large-Cap Healthcare Stocks To Watch

    August 18, 2014
    Healthcare continues to a be a hot sector. Here are four pharma stocks to keep an eye on for entry points.
  6. Interested In Healthcare Stocks? Look At This ETF

    July 3, 2014
    Healthcare companies seem to be poised to make a move higher over the months ahead. Here's an ETF that should be helpful ...
  7. What Are The Best Bets In Biotech?

    May 2, 2014
    The NASDAQ Biotechnology Index is off nearly 20% as its components busy themselves with hostile bids and frenzied buying ...
  8. 7 ETF Types To Be Thankful For

    November 28, 2013
    This year has shaped up to be quite kind to investors as major equity indexes are holding onto double-digit gains ahead of ...
  9. A Strong Prognosis For Healthcare Stocks

    November 19, 2013
    Despite the healthcare sectors recent torrid run, there’s still plenty to like about stocks in the industry. Aside from tailwinds ...
  10. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  11. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  12. Amgen Sweetens The Bid And Secures Onyx

    August 26, 2013
    Amgen finalizes a value-additive deal for Onyx
  13. Can Sanofi Investors Just Blame It On Rio?

    August 6, 2013
    Can Sanofi Investors Just Blame It On Rio? By Stephen D. Simpson, CFA Sanofi (NYSE: SNY) was supposed to be a relatively ...
  14. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  15. Wall Street Happy To Hum La AbbVie En Rose

    July 26, 2013
    AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
  16. Amgen Puts Onyx Pharmaceuticals In Play

    July 2, 2013
    An unsolicited $120/share bid has sent Onyx soaring and rival bidders circling.
  17. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  18. 10 Picks from 2 Strong Sectors

    June 10, 2013
    As we enter the bumpy summer months, large-cap US domestic stocks and health-care names are on Louis Navellier's list, and ...
  19. Alnylam Basking In Orphan Drug Attention

    May 28, 2013
    Alnylam has already seen a big run, but clinical success could bring even more gains.
  20. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  21. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  22. Amgen and Other Healthcare Stocks Making Big Moves on October ...

    October 19, 2012
    The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is down ...
  23. It's Time to Sell These 4 Surging Stocks

    October 19, 2012
    With the S&P 500 surging roughly 25% in the past 12 months, it's been a great time to have full exposure to the stock ...
  24. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  25. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  26. Healthcare Stocks Continuing To Outperform

    July 18, 2012
    These healthcare stocks are still on fire, with potentially more upside left. But is that actually bad for the stock market?
  27. ilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company

    May 22, 2012
    Agilent is paying up to get into the increasingly crowded diagnostics market.
  28. Biotech ETFs Hitting Highs

    May 17, 2012
    Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% in 2 ...
  29. AstraZeneca Searches For Answers

    May 3, 2012
    AstraZeneca has an opportunity to do something big when it brings in a new CEO.
  30. 4 ETFs On Fire Right Now

    February 3, 2012
    The commodities market had some of the best-performing ETFs of January.
  31. Big Buys In Share Buybacks

    January 27, 2012
    Record corporate profits and super low interest rates are resulting in a shrinking market environment and a rise in share ...
  32. Be Your Own Venture Capitalist With These Stocks

    September 16, 2011
    By doing some digging, there are ways for the average joe to become his/her own venture capital fund.
  33. A Deal At Last For Sanofi And Genzyme

    February 18, 2011
    Though Sanofi finally got its way in acquiring Genzyme, time will determine if stockholders will truly benefit.
  34. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  35. Getting In On Growth At A Great Price

    July 5, 2010
    Here are some growth-oriented stocks with below-market average P/Es that investors can pick up during this shaky market to ...
  36. Biotech Bargains

    June 17, 2010
    High-growth biotech stocks are now priced like value plays.
  37. The 5 Most Important Drugs In America

    July 28, 2009
    A look at the top-selling drugs finds that a few that make more of a difference to the company's bottom line than others.
  38. Two More Reasons To Diversify

    June 3, 2009
    GM and Citigroup being removed from the DJIA should cause investors to focus on diversification.
  39. Convertible Securities In Today's Market

    April 30, 2009
    John Calamos, the father of convertible investing, moderated a panel on convertible bonds at the Milken Global Conference ...
  40. Dark Horse Candidates To Enter The Dow

    March 4, 2009
    The DJIA is sure to be rebalanced over the next year as some members teeter on bankruptcy or face falling from the index.
  41. Buyer Beware In Biotech ETFs

    August 27, 2007
    The biotech sector has been flat this year, and the five biotech ETFs have been hit and miss - mainly miss.
  42. Up on Amgen (AMGN)

    April 30, 2007
    Amgen shares are in a rut, and that could signal opportunity for investors.
Trading Center